SP
Spero Therapeutics, Inc.
SPRO · NASDAQ
$1.17 -2.50% (-$0.03)
1M -4.88%
Market Cap $67.7M
P/E Ratio 9.18x
Div. Yield -
ROE 16.17%
Piotroski F-Score Moderate
6/9Valuation
99 /100
Cheap P/E 9.18x
EV/EBITDA 2.47x
P/FCF 3.46x
Growth
42 /100
Stable Rev. growth 7.06%
Book val. growth 8.06%
EPS growth N/A
Profitability
87 /100
Strong Gross margin 100.00%
Net margin 17.18%
FCF margin 45.57%
Quality
75 /100
Excellent ROIC 12.56%
ROE 16.17%
Asset turnover 0.81x
Debt
100 /100
Low Debt/Equity 0.05x
Current ratio 6.12x
Net debt/EBITDA -6.33x
Stability
12 /100
Unstable Beta 1.48x
Rev. volatility 83.77%
Profitable years 1
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o SPRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Esther Rajavelu
Employees
25
Headquarters
Cambridge
Nadchodzące wydarzenia
12 LIS
Earnings
Upcoming earnings report